MARKET

BNTX

BNTX

BIONTECH
NASDAQ
87.01
-1.64
-1.85%
After Hours: 87.00 -0.01 -0.01% 19:39 04/11 EDT
OPEN
89.64
PREV CLOSE
88.65
HIGH
89.64
LOW
86.81
VOLUME
574.54K
TURNOVER
0
52 WEEK HIGH
131.52
52 WEEK LOW
85.21
MARKET CAP
20.68B
P/E (TTM)
20.57
1D
5D
1M
3M
1Y
5Y
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
Investorplace · 2d ago
BioNTech SE Virtual AGM Scheduled for May 2024
TipRanks · 3d ago
BioNTech Reports Promising Cancer Vaccine Data
TipRanks · 4d ago
Weekly Report: what happened at BNTX last week (0401-0405)?
Weekly Report · 4d ago
Reported Sunday, BioNTech Three-Year Phase 1 Follow-Up Data For mRNA-based Individualized Immunotherapy Candidate Shows Persistence Of Immune Response And Delayed Tumor Recurrence In Some Patients With Resected Pancreatic Cancer
Autogene cevumeran shows polyspecific T cell responses up to three years and delayed tumor recurrence in patients with resected pancreatic ductal adenocarcinoma. The medical need in PDAC is high with a 5-year overall survival rate of only 8-10%.
Benzinga · 4d ago
BRIEF-Phase I Data Show Polyspecific T Cell Responses Up To Three Years And Delayed Tumor Recurrence In Patients With Resected Pancreatic Ductal Adenocarcinoma (“PDAC”)
BioNTech says phase I data show Polyspecific T Cell Responses Up To Three years And Delayed Tumor Recurrence In Patients With Resected Pancreatic Ductal Adenocarcinoma. The drug is being tested on patients with the disease.
Reuters · 4d ago
CureVac, GS Partner Release Data On Influenza Vaccine Study
CureVac N.V. Released interim data on its seasonal influenza vaccine candidate. The study is part of a collaboration with GSK Plc. The multivalent candidate is designed for broad antigen coverage and is matched to all four WHO-recommended flu strains.
Benzinga · 04/04 16:18
Weekly Report: what happened at BNTX last week (0325-0329)?
Weekly Report · 04/01 09:05
More
About BNTX
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Webull offers BioNTech SE - ADR stock information, including NASDAQ: BNTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BNTX stock methods without spending real money on the virtual paper trading platform.